Fremanezumab
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
- Fremanezumab
- Fremanezumab: From Migraine (Episodic/Chronic) Prevention to Migraine with Brainstem Aura
Fremanezumab: From Migraine (Episodic/Chronic) Prevention to Migraine with Brainstem Aura
One-Sentence Summary
Fremanezumab is a fully humanized anti-CGRP monoclonal antibody approved for the preventive treatment of episodic and chronic migraine. The TxGNN model predicts it may also be effective for Migraine with Brainstem Aura, a rare migraine subtype involving posterior-circulation symptoms. Currently no dedicated clinical trials and 20 publications (mostly preclinical, case reports, and general real-world migraine cohorts) support this specific direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no local (Norway) marketing authorization on file; per the evidence pack's mechanistic notes, fremanezumab is approved for episodic/chronic migraine prevention |
| Predicted New Indication | Migraine with Brainstem Aura |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L3 |
| Norway Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed DrugBank mechanism-of-action data for fremanezumab is not available in this evidence pack (flagged as a data gap, DG002). However, the evidence itself indicates that fremanezumab is a fully humanized anti-CGRP monoclonal antibody, already approved for prevention of episodic and chronic migraine, acting by inhibiting CGRP-mediated activation of the trigeminovascular system.
Migraine with brainstem aura (formerly "basilar-type migraine") is a rare migraine subtype in which typical aura symptoms are accompanied by brainstem/posterior-circulation features. Because fremanezumab's approved use already spans migraine broadly, and preclinical models show it can modulate cortical spreading depression (CSD) — the presumed electrophysiological substrate of migraine aura — there is a plausible mechanistic rationale for extending its use to aura-associated subtypes.
That said, the mechanistic link is only partial: animal studies (PMID 31127003, PMID 31895266) show fremanezumab slows CSD propagation rate and shortens cortical recovery time, but does not prevent CSD-induced arterial dilatation or plasma protein extravasation — meaning the drug does not fully block the vascular component of the aura mechanism. In addition, brainstem aura is a rare subtype historically excluded from pivotal CGRP-mAb trials (e.g., FOCUS), so direct clinical evidence is limited to case reports and reviews on migraine aura/hemiplegic migraine, plus general real-world cohorts of chronic migraine patients not specifically enrolled for the brainstem-aura subtype.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 41618146 | 2026 | Individual patient analysis | The Journal of Headache and Pain | Effectiveness and safety of anti-CGRP mAbs (incl. fremanezumab) in hemiplegic migraine, a related aura subtype historically excluded from RCTs |
| 40264646 | 2025 | Case report + review | Frontiers in Neurology | Anti-CGRP mAb efficacy in hemiplegic migraine; role in aura subtypes remains largely unexplored due to RCT exclusion |
| 35268319 | 2022 | Case reports/Review | Journal of Clinical Medicine | Reviews anti-CGRP mAbs (incl. fremanezumab) in migraine aura prevention; scarce data on aura-specific efficacy |
| 38332541 | 2024 | Observational case series | CNS Neuroscience & Therapeutics | Limited clinical evidence on anti-CGRP mAb effectiveness for preventive treatment of migraine with aura |
| 31127003 | 2019 | Animal/Mechanistic | J Neuroscience | Fremanezumab does not affect CSD-induced arterial dilatation/plasma protein extravasation — partial mechanistic engagement with aura |
| 31895266 | 2020 | Animal/Mechanistic | Pain | Fremanezumab slows CSD propagation and shortens cortical recovery, but does not prevent CSD occurrence |
| 35302681 | 2022 | Cohort (real-world) | European Journal of Neurology | Post hoc FOCUS analysis: fremanezumab efficacy/QoL outcomes in patients with vs. without aura or neurological dysfunction |
| 35775208 | 2022 | Pending classification | Cephalalgia | Effects of anti-CGRP mAbs (erenumab, fremanezumab, galcanezumab) on migraine prodromal/accompanying and central symptoms |
| 37638190 | 2023 | Cohort (real-world) | Frontiers in Neurology | Real-world efficacy and tolerability of fremanezumab in chronic migraine (general population, 3-month prospective study) |
| 30725283 | 2019 | Review | Handbook of Experimental Pharmacology | Overview of CGRP's role in migraine pathophysiology, including the aura subgroup |
Norway Market Information
Fremanezumab currently has no marketing authorization on file for Norway (0 authorizations; market status: Not Marketed).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale:
- Evidence level L3 rests on preclinical/mechanistic studies and general real-world migraine cohorts rather than trials targeting migraine with brainstem aura specifically; this subtype has historically been excluded from pivotal CGRP-mAb trials, and the drug has no current marketing authorization in Norway.
To proceed, the following is needed:
- Formal DrugBank/TFDA mechanism-of-action and labeling data (DG002, DG001)
- A dedicated clinical trial or systematic case series in patients with confirmed migraine with brainstem aura
- Local (Norway) regulatory/market-authorization status update
- Standard safety profile (warnings, contraindications, DDI) once labeling data becomes available
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.